Navigation Links
Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Date:8/22/2007

MENLO PARK, Calif. and HUNTSVILLE, Ala., Aug. 22 /PRNewswire/ -- DNA2.0 Inc. (http://www.DNA20.com), the largest US provider of synthetic genes, and Operon Biotechnologies (http://www.operon.com), a leader in DNA oligonucleotide synthesis, announce the formation of a partnership to utilize their synergistic technologies and product lines.

By combining Operon's oligonucleotide production platform with DNA2.0's gene synthesis process, the companies expect to further increase DNA2.0's market leading speed of synthesis, while providing Operon access to the fastest growing application area for oligonucleotides today. The partnership will allow each company to remain focused on their respective core businesses, while the customer benefits from the expertise of both partners.

Under the partnership, Operon will co-market DNA2.0's gene synthesis services. 'DNA2.0 provides products and a level of customer service that is unparalleled in the gene synthesis industry, we wholeheartedly recommend them to our customers for their synthetic genes.' said Patrick A. Weiss, CEO of Operon. 'We at Operon are proud to be the primary source of the oligos that go into DNA2.0 synthetic genes.'

'Construction of synthetic genes requires oligos of only the highest quality' said Jeremy Minshull, President of DNA2.0. 'Operon's fully automated oligo synthesis process meets our exacting quality requirements, and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene synthesis marketplace.'

About DNA2.0 Inc.

DNA2.0 is the largest US provider of synthetic genes, serving customers globally in the pharmaceutical and biotechnology industries as well as in academia. The company is also pioneering the application of machine learning to commercial protein engineering through their ProteinGPS(TM) platform. For more information please visit http://www.DNA20.com.

About Operon Biotechnologies

Operon Biotechnologies is a global market leader in high-throughput synthesis, serving scientists in academic research, biotechnology, and pharmaceutical development. Through our production facilities in the US, Germany, and Japan, as well as distributors worldwide, Operon provides a wide range of quality DNA oligonucleotides, Array Ready Oligo Sets (AROS(TM)) and pre-printed microarrays (OpArray(TM)). Since its inception in 1986, Operon has been driven by incomparable customer service and reliable delivery of quality products. Operon employs advanced synthesis technologies and consistently pursues unique innovations to maintain the highest level of excellence in both products and support. For more information please visit http://www.operon.com.


'/>"/>
SOURCE Operon Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... ... sources for advanced technology applications, has announced a facility expansion to accommodate its ... 3,000 square feet of new workspace and renovation of the existing areas. The ...
(Date:5/23/2017)... ... 23, 2017 , ... Customers often prefer PLC and ... again. METTLER TOLEDO has released two new videos that show how they have ... the ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... meeting and educational conference of the American Association of Bioanalysts (AAB) and the ... Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of the ... Of Wales Private Hospital. The procedure was performed on a 46-year-old male patient ... treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):